Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
复制标题
DOI：
10.2165/00003495-200969020-00006
复制
发表时间：
2009-01-01
期刊：
影响因子：
11.5
通讯作者：
Santoro, Armando
中科院分区：
文献类型：
--
作者：
Keating, Gillian M.;Santoro, Armando
索拉非尼（Nexavar（R））是一种口服活性多激酶抑制剂，在欧盟被批准用于治疗肝细胞癌。索拉非尼单药治疗可延长晚期肝细胞癌患者的总生存期，并延迟其进展时间，这些患者不适合进行潜在的治愈性治疗或经动脉化疗栓塞。索拉非尼在晚期肝细胞癌患者中通常耐受良好。因此，索拉非尼代表了治疗晚期肝细胞癌的一个重要进展，是治疗这种疾病的新标准。
Sorafenib (Nexavar (R)) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization. Sorafenib is generally well tolerated in patients with advanced hepatocellular carcinoma. Thus, sorafenib represents an important advance in the treatment of advanced hepatocellular carcinoma and is the new standard of care for this condition.